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Abstract: Type 2 diabetes (T2D) is a complex disease that is caused by a complex interplay 
between genetic, epigenetic and environmental factors. While the major environmental 
factors, diet and activity level, are well known, identification of the genetic factors has been 
a challenge. However, recent years have seen an explosion of genetic variants in risk and 
protection of T2D due to the technical development that has allowed genome-wide 
association studies and next-generation sequencing. Today, more than 120 variants have 
been convincingly replicated for association with T2D and many more with diabetes-related 
traits. Still, these variants only explain a small proportion of the total heritability of T2D.  
In this review, we address the possibilities to elucidate the genetic landscape of T2D as well 
as discuss pitfalls with current strategies to identify the elusive unknown heritability 
including the possibility that our definition of diabetes and its subgroups is imprecise and 
thereby makes the identification of genetic causes difficult. 
Keywords: type 2 diabetes; genetics; heritability; genome-wide association studies; 
common variants; rare variants; parent-of-origin; systems biology 
 
1. The Diabetes Epidemic 
Diabetes refers to a group of metabolic diseases characterized by hyperglycemia resulting from 
defects in insulin secretion, insulin action, or both [1]. The chronic hyperglycemia of diabetes is 
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associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, 
kidneys, nerves, heart, and blood vessels. Diabetes is currently the fastest-growing epidemic and has 
been ascribed to a collision between genes and the environment. Worldwide prevalence figures estimate 
that there were 382 million people living with diabetes in 2013 and that by 2035 this number will have 
risen to 592 million [2]. India and China have the highest reported prevalences of diabetes with 65 and 
98 million in 2013, respectively, More than 90% of these cases are considered as T2D. In Europe,  
~8% of the population is affected by diabetes, 90% of which is accounted for by T2D, making T2D the 
fastest-increasing disease in Europe and worldwide [2,3]. 
The T2D epidemic can largely be ascribed to the worldwide increase in obesity during the last 30 years, 
for instance, more than 60% of individuals older than 15 in the UK and US are overweight (BMI > 25) [4]. 
This has been ascribed to a collision between genes and the environment. The social determinants of 
environmental factors tend to vary across populations and have changed rapidly over the last decades. 
A traditional high energy-burning lifestyle has been replaced by a Western sedentary lifestyle with little 
or no exercise and consumption of an energy-dense diet. Meanwhile, genetic factors evolve at a slower 
rate across generations, and tend to favor selection of “energy-saving thrifty genotypes,” which might 
have been beneficial for individuals living in times of unstable food supply by storing energy in times 
of surplus [5]. While this hypothesis provides an appealing explanation to the obesity and T2D epidemic, 
formal proof for this hypothesis is still lacking. 
Advances in genomic technology have initiated a myriad of novel genetic discoveries including more 
than 2,000 common variants contributing to risk of complex disease. While we have learned a great deal, 
a new biology about pathogenesis of these variants can only explain only a small portion of the total 
heritability of diabetes, leaving much of the underlying mechanisms unknown. The current review will 
try to explore the pitfalls with current strategies and elucidate possibilities to use genetics to enhance 
our understanding of the disease. 
2. The Diabetes Spectrum 
Diabetes encompasses a range of heterogeneous metabolic disorders characterized by the inability of 
the body to assimilate glucose and maintain glucose homeostasis. Diabetes has been traditionally 
subdivided into type 2 diabetes (T2D) and type 1 diabetes (T1D). However, this is a gross oversimplification 
of a rather complex situation. The concept of diabetes has grown over the past decades to the 
understanding that several different overlapping contributions from genetics and environment can lead 
to manifestations of varying forms disease. Contrary to being dichotomously distinct disorders, T1D and 
T2D can be considered rather as the two ends of a diabetes spectrum, with the intermediates comprising 
of maturity-onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA) and 
other subtypes. 
Type 1 diabetes (T1D), also known as juvenile diabetes or insulin-dependent diabetes, is a chronic 
condition which is due to autoimmune destruction of pancreatic beta cells and is characterized by 
(nearly) complete absence of insulin secretion, and presence of autoantibodies including glutamic acid 
decarboxylase (GAD) antibodies, leading to dependence on insulin injections. It is most often diagnosed 
in children, adolescents or young adults less than 35 years old. The incidence of T1D varies based upon 
geography, age, gender, and family history [2].Only 10% to 15% of newly diagnosed patients have a 
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positive family history of T1D [6]. However, increased susceptibility to T1D can be inherited, because 
the average prevalence risk is 0.4% for children with no family history whereas ~6% when either parent 
has T1D, >30% when both parents are affected. There is a great difference in recurrence risk between 
dizygotic (8%) and monozygotic (50%) twins (30% risk within 10 years of diagnosis of the first  
twin) [7,8]. Interestingly, the risk in offspring of an affected mother is 2%–4%, whereas the risk of an 
affected father is as high as 5%–8% [9,10]. The sibling relative risk of T1D is estimated at 15 [7,11,12]. 
T1D results from interplay between genetic, epigenetic and environmental factors [13]. Genetic studies 
have been able to explain 80% of the heritability of T1D [14]. The main susceptibility genes currently 
accepted for T1D are the HLA class II alleles, which account for up to 50% of genetic T1D risk and  
non-HLA loci including the insulin gene, CTLA4, PTPN22, interleukin 2 receptor a (IL2RA), and others [15]. 
Environmental factors suggested so far include enterovirus infections including viruses of the picoRNA 
family, as they are seen more often among newly diagnosed T1D individuals than in the general 
population, and they precede the appearance of autoantibodies, environmental pollutants, gut flora 
variations and vitamin D exposure [16–18]. 
LADA (Latent Autoimmune Diabetes in Adults) is a common subgroup of diabetes accounting for 
about 7% of all diabetic patients in Europe. LADA is usually defined as GAD antibody-positive diabetes 
with onset greater than 35 years of age and no insulin requirement during the first 6 months after 
diagnosis [19–21]. The cutoff for defining GAD ab positivity is the same as for T1D. Therefore, LADA 
with high ab titers are found to the left of the spectrum close to T1D, whereas LADA with lower titers 
are to the right of the spectrum close to T2D [22]. A family history of any form of diabetes is a strong 
risk factor for the development of LADA [23]. 
MODY (Maturity-Onset-Diabetes of the Young) refers to monogenic forms of diabetes with  
well-defined mutations in more than 10 different genes, and this number is still increasing. The disease 
is characterized by autosomal dominant transmission of early-onset (<25 years) diabetes and varying 
degree of beta-cell dysfunction [24]. It was long debated whether the MODY genes would harbor 
common less-penetrant variants increasing risk of T2D; now, this seems to be the case for most of them 
including HNF1A, HNF4A, HNF1B, GCK, and PDX1 [25–27]. MODY shows extreme allelic heterogeneity 
meaning that most MODY mutations are unique; to date, there are more than 200 mutations described 
in the GCK (MODY2) and HNF1A (MODY3) genes [28,29]. The appropriate diagnosis of MODY requires 
sequencing. With the advent of next-generation sequencing technologies, accurate MODY diagnoses are 
much more feasible today.  
Maternally inherited diabetes and deafness (MIDD) is due to the A3242G mutation in 
mitochondrial DNA (mtDNA) [28,30]. As mtDNA is only transmitted from the mother, MIDD shows 
maternal transmission. In addition to hearing loss, many patients also display neurological problems 
similar to patients with the MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic 
acidosis, and stroke), which is also caused by the same mutation in mtDNA. 
Neonatal diabetes is defined as diabetes with onset at birth or during the first 6 months of life with 
both transient and permanent forms [28]. Mutations in several genes have been shown to cause neonatal 
diabetes (KCJN11, SUR1, GCK, INS, etc.), and an appropriate genetic diagnosis is a prerequisite for 
optimal treatment. Patients with mutations in the KCJN11 gene do not only have severe diabetes but also 
developmental defects (DEND). These conditions are improved after switching from insulin treatment 
to treatment with large doses of sulfonylureas [31]. 
Genes 2015, 6 90 
 
 
Gestational Diabetes mellitus (GDM) is a transitory form of diabetes which manifests as 
hyperglycemia during pregnancy which is clearly not overt diabetes and resolves itself post-partum.  
An estimated sibling risk ratio of 1.75 was reported for GDM [32,33]; however, changes in the diagnostic 
criteria have complicated retrospective identification of GDM cases and correct estimation of heritability. 
It has been observed that many of the GDM-associated variants overlap with T2D risk variants [34–36] 
which may partly explain the increased risk for T2D in women with previous GDM [37,38]. Despite 
being a transient condition, women with GDM are at increased risk for adverse pregnancy outcomes and 
fetal hyperinsulinism, and infants with macrosomia [39,40]. 
Type 2 diabetes is the most prevailing form, constituting 80%–90% of all reported diabetes cases.  
T2D is the result of a complex interplay between genetic, epigenetic and environmental factors.  
T2D develops when pancreatic beta cells can no longer produce enough insulin to compensate for the 
insulin resistance imposed by increasing obesity. There is no formal definition of T2D; patients who do 
not fulfill criteria of T1D, LADA, secondary diabetes (see below), or monogenic forms of diabetes are 
considered to have T2D. T2D is more often associated with increased age, wherein age of onset is usually 
over 35 years [14]. However, it is increasingly reported in adolescents in high risk countries such as 
India AND China [3]. Heritability of T2D is discussed below. 
Finally, diabetes can develop secondary to pancreatic disease or other endocrine disorders and 
referred to as secondary diabetes. 
All these forms of diabetes represent a range of genetic etiologies from the monogenic MODY 
variants to T2D, which is a complex heterogeneous polygenic disease with a strong environmental 
component. The ANDIS (All New Diabetics in Scania) project in southern Sweden represents a new 
attempt to reclassify diabetes into subgroups based upon genetic markers and biomarkers (Figure 1).  
The aim of ANDIS is to register all new cases of diabetes in Scania and improve diagnosis and treatment 
strategies. At the time of registration, blood samples are drawn to determine the presence of GAD antibodies, 
measure C-peptide, biobanking and for genetic analysis. The genetic data is used to classify the disease 
into subtypes and to study genetic causes of diabetes, diabetic complications and other disorders related 
to diabetes (http://andis.ludc.med.lu.se/all-new-diabetics-in-scania-andis/). A similar project has been 
initiated in Uppsala with the same goal (ANDIU—All new diabetics in Uppsala). The ANDIU study 
design is similar to the ANDIS study (http://www.andiu.se/english/). 
3. Heritability of T2D 
T2D clusters in families and it is well established that the risk of developing T2D depends on both 
genetic and environmental factors. However, heritability estimates have varied between 25%–80% in 
different studies; the highest estimates are seen in those studies with the longest follow-up periods. The 
lifetime risk of developing T2D is 40% for individuals who have one parent with T2D and almost 70% if 
both parents are affected [41]. Furthermore, the concordance rate of T2D in monozygotic twins is about 70%, 
while the concordance in dizygotic twins is only 20%–30%. The proband-wise concordance rates (number 
of affected twins having a diabetic co-twin) for monozygotic twins vary between 34% and 100% [42–45]. 
The relative risk for first degree relatives, i.e., the risk of developing T2D if you have an affected 
parent or sibling compared to the general population, is approximately 3, and ~6 if both parents are 
affected [46]. However, these figures vary depending on the cohort and population studied. 
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The prevalence of T2D varies widely among populations, from a few percent among Caucasians in 
Europe to as high as 50% among Pima Indians in Arizona [47]. While part of the observed ethnic 
variability could be attributed to environmental and cultural factors, some of the variation seems to 
depend on genetic differences. 
In spite of these reservations, there is no doubt the risk of T2D is partly determined by genetic factors, 
many of which have already been identified, and while each identified variant explains only a very small 
proportion of the risk of T2D in the human population, they have contributed to our understanding of 
disease pathogenesis. One should also keep in mind that the variance explained by a risk allele in a 
population is not necessarily an indicator of its importance in specific patients, nor is it proportional to 
the affected pathway’s importance or potential as a therapeutic target. 
 
Figure 1. The spectrum of diabetes subgroups. The data is from the ANDIS project  
(All New Diabetics in Scania) (http://andis.ludc.med.lu.se) in April 2012 which at that time 
included 5,800 newly diagnosed diabetic patients aged 0–100 years. The criteria used for 
diagnosis are as follows: T1D: age at onset <35 years, C-peptide < 0.2nmol/L and GAD 
antibodies >20; T1D with relative insulin deficiency if C-peptide 0.2–0.6 nmol/L. T2D: age 
at onset >35 years, C-peptide > 0.6 nmol/L, GAD antibodies <10; T2D with relative insulin 
deficiency C-peptide 0.2–0.6 nmol/L. LADA (latent autoimmune diabetes in adults): age at 
onset > 5 years, GAD antibodies >20; LADA light if GAD antibodies 10–20. The data clearly 
illustrates the difficulty classifying diabetic patients at diagnosis with 19% unclassifiable. 
4. Possibilities 
4.1. Search for the Genetic Basis of T2D 
4.1.1. Linkage Studies 
The CAPN10 gene on chromosome 10 encoding calpain 10, a cysteine protease with largely unknown 
functions in glucose metabolism, was the first T2D susceptibility gene to be identified through linkage 
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studies [48]. Unfortunately, this locus has been difficult to replicate in subsequent studies. The greatest 
success in linkage studies relates to the discovery of variants in the TCF7L2 as being associated with 
T2D. The DeCode team observed a rather modest linkage at a 10.5 Mb region on chromosome 10q, but 
decided to pursue and fine-map it thereby identifying the variant until the date showing the strongest 
association with T2D, an intronic variant (rs7903146) in the TCF7L2 gene contributing to, but not fully 
explaining, the original linkage [49–51]. This association has since been confirmed in African, Asian 
and European populations rendering it the most consistently replicated genetic association with T2D to 
date, conferring a relative risk of ~1.4 [52]. 
4.1.2. Candidate Genes for T2D 
The first candidate gene reproducibly associated with T2D was PPARG, encoding the nuclear 
receptor PPAR- [53]. The PPAR- receptor is a molecular target for thiazolidinediones, a class of 
insulin-sensitizing drugs used to treat T2D, making it a very compelling candidate gene. The transcript 
expressed in adipose tissue has an extra exon B and a substitution of a proline for alanine at position 12 
of this protein, which is seen in about 15% of the European population. This variant has been shown to 
be associated with increased transcriptional activity, increased insulin sensitivity and protection against 
T2D [53]. 
T2D risk variants in KCJN11 were also discovered through candidate association studies [54,55]. 
KCNJ11 codes for four subunits of the ATP-sensitive potassium (K-ATP) channel, the other four coded 
by another gene (ABCC8). The E23K polymorphisms in KCNJ11 and P12A in PPARG putatively acted 
in an additive manner to increase T2D risk [56]. In pancreatic beta cells, ATPpotassium channels are 
crucial for the regulation of glucose-stimulated insulin secretion and are the target for the sulfonylureas 
which are oral hypoglycemic agents widely used in the treatment of T2D and for diazoxide, a potassium 
channel opener. Activating mutations in this gene also caused neonatal diabetes. Additionally,  
loss-of-function mutations in KCNJ11 and ABCC8 caused hyperinsulinemia in infancy [57]. 
4.1.3. Genome Wide Association Studies (GWAS) 
The development of new genotyping technologies and the realization that we inherit stretches of the 
genome together as haplotypes facilitated the cataloging of common variants (HAPMAP, 1000 
genomes) and allowed for new possibilities to apply unbiased global approaches to screen millions of 
common variants for association with complex diseases. Several GWAS for diabetes were published in 
2007, coined “Breakthrough of the Year” by Science magazine. The first was a GWAS on early-onset 
T2D reporting two new diabetes loci: HHEX and SLC30A8 [58]. The ultimate proof of the value of 
GWAS for T2D came from three GWAS published back to back in Science in 2007; for the first time in 
the genetics of T2D, three different studies reported the same top findings [59–61]! 
The first wave of GWAS was followed by a second wave combining existing or new GWAS into 
meta-analyses of >50,000 individuals [25]. A prerequisite for this was that many research groups could 
work together in consortia like DIAGRAM (DIAbetes Genetics Replication and Meta-analysis Consortium) 
and MAGIC (Meta-Analyses of Glucose-and Insulin-related traits Consortium). GWAS do not inevitably 
lead to identification of a gene or genes in a given locus associated with disease. Since the most strongly 
associated single nucleotide polymorphisms (SNPs) are often only markers for the functional variant 
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responsible for the observed genetic effect and most associated regions harbor several genes, additional 
fine mapping of the loci in even larger sample sets is often necessary. To do this cost efficiently, a 
custom-designed chip, the so-called CardioMetabochip (Illumina) was been developed for 
metabolic/cardiovascular gene mapping. This chip contains ~200,000 polymorphisms selected to cover 
association signals from a wide range of metabolic disorders (T2D, lipid disorders, obesity and 
cardiovascular disease), and was designed to perform both deep replication of major disease signals and 
fine mapping of established loci. Meta-analysis of previous GWAS by the DIAGRAM consortium with 
an additional 22,669 T2D cases and 58,119 controls genotyped using the CardioMetabochip has recently 
added another eight new loci associated with T2D in the European population and 2 novel loci not 
previously reported in populations of European descent [62]. 
Recently, a number of GWAS and meta-analysis studies have also been performed in non-European 
cohorts, adding several new loci to the list of genome-wide significant associations [63–70]. 
Interestingly, it seems like most associations found in one ethnic group also show some evidence of 
association in populations with other ethnicities. Association of the same variants in more than one 
population adds to the robustness of the association. KCNQ1, for instance, was reported simultaneously 
as a T2D risk allele in two studies based on East Asian populations and further replicated in the European 
population as well [71,72]. Similarly, variants in UBE2E2, C2CD4A-C2CD4B, ANK1, GRK5, RASGRP1, 
PAX4 and others were discovered in the East Asian population and replicated in Caucasians with variants 
in PPAR, KCNJ11, TCF2, TCF7L2, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2, 
whereas variants in MTNR1B, SLC30A8, KCNQ1, CDC123, GLIS3, HNF1B, DUSP9 and others were 
identified in Caucasian populations and were also replicated in East Asian populations [63–70,73].  
In addition, there are also some population specific risk variants whose association with T2D risk in other 
populations is yet to be ascertained. For instance, variants in GLIS3, PEPD, ITM2-R3HDML-HNF4A, 
KCNK16, MAEA, GCC1-PAX4, PSMD6, and ZFAND were discovered in populations of East  
Asian descent, SLC16A11 in the Mexican population, and TMEM163 in chr 2 in a North Indian 
population [63,74–76]. 
Trans-ethnic GWAS have been highly effective in the discovery of complex trait loci, and provide 
valuable insights into the genetic architecture of T2D across populations of diverse ancestry [70].  
In addition, they enable fine-mapping by taking advantage of differences in genomic linkage 
disequilibrium across ethnically diverse populations, and facilitate prioritization of candidate genes [77]. 
However, allele frequencies can vastly vary between diverse populations and in terms of effects, and 
need to be taken into consideration while performing such meta-analyses. A method which takes into 
consideration the expected similarity in allelic effects between the most closely related populations, 
while allowing for heterogeneity between more diverse ethnic groups has been proposed to allow  
for this [78]. 
In total, GWAS have provided ~153 variants for T2D mapping to >120 loci (Table 1, Figures 2 and 3) 
as well as numerous loci for glucose or insulin-related traits (Table 2) and more are likely to come. 
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Table 1. Genetic loci associated with risk of T2D. 
N T2D Risk SNP Gene/Nearest Gene Gene Location Chr RA OA OR TRAIT Refs. 
1 rs17106184 FAF1 intron 1 G A 1.10 T2D [70] 
2 rs2296172 MACF1 coding - missense 1 G A 1.10 2D [79] 
3 rs10923931 NOTCH2 intron 1 T G 1.13 T2D [4,80] 
4 rs340874 PROX1 intergenic 1 C T 1.07 Fasting glucose/HOMA B/T2D [81] 
5 rs243021 BCL11A intergenic 2 A G 1.08 T2D [25] 
6 rs243088 BCL11A intergenic 2 T A 1.07 T2D [62] 
7 rs2975760 CAPN10 intron 2 C T 1.17 T2D [48,82] 
8 rs3792267 CAPN10 intron 2 G A 1.17 T2D [48,82] 
9 rs7607980 COBLL1 coding-missense 2 T C 1.14 T2D [79] 
10 rs560887 G6PC2/ABCB11 intron 2 T C 1.03 Fasting glucose/T2D/HOMA B [81] 
11 rs780094 GCKR intron 2 C T 1.06 T2D/Fasting glucose/beta-cell function/triglycerides/fasting insulin [81] 
12 rs3923113 GRB14 intergenic 2 A C 1.07 T2D [62,65] 
13 rs13389219 GRB14 intergenic 2 C T 1.07 T2D [62] 
14 rs2943641 IRS1 intergenic 2 C T 1.19 Fasting glucose/T2D/HOMAB, HOMA IR/AUC ins/AUC ratio/ISI [83] 
15 rs7578326 KIAA1486/IRS1 
intron of uncharacterized 
LOC646736 
2 A G 1.11 T2D [25] 
16 rs7593730 RBMS1/ITGB6 intronic 2 C T 1.11 T2D [84] 
17 rs7560163 RND3 intergenic 2 G C 1.33 T2D [67] 
18 rs7578597 THADA coding-missense 2 T C 1.15 T2D [4,80] 
19 rs10200833 THADA intron 2 G C 1.06 T2D [80,85] 
20 rs6723108 TMEM163 intergenic 2 T G 1.31 Decreased fasting plasma insulin/HOMA-IR/T2D [74] 
21 rs998451 TMEM163 intron 2 G A 1.56 Decreased fasting plasma insulin/HOMA-IR/T2D [74] 
22 rs4607103 ADAMTS9-AS2 intron 3 C T 1.09 T2D [4,80] 
23 rs6795735 ADAMTS9-AS2 intron 3 C T 1.09 T2D [4,80] 
24 rs11708067 ADCY5 intron 3 A G 1.12 T2D/2hr glucose/HOMA B [81,86] 
25 rs2877716 ADCY5 intron 3 C T 1.12 2 h insulin adjusted for 2 h glucose/2 h glucose/T2D [81,86] 
26 rs11071657 FAM148B intergenic 3 A G 1.03 Fasting glucose/T2D/HOMA B [81] 
27 rs4402960 IGF2BP2 intron 3 T G 1.11 T2D [59] 
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Table 1. Cont. 
N T2D Risk SNP GENE/Nearest Gene Gene Location Chr RA OA OR TRAIT Refs. 
28 rs1470579 IGF2BP2 intron 3 C A 1.15 T2D [26,59,72,87] 
29 rs6808574 LPP intergenic 3 C T 1.07 T2D [70] 
30 rs1801282 PPARG coding-missense 3 C G 1.09 T2D [59] 
31 rs13081389 PPARG intergenic 3 A G 1.24 T2D [25,53,59,87] 
32 rs17036160 PPARG intron 3 C T 1.11 T2D [85] 
33 rs1797912 PPARG intron 3 A C 1.06 T2D [85] 
34 rs831571 PSMD6 intergenic 3 C T 1.09 T2D [63] 
35 rs7647305 SFRS10 intergenic 3 C T 1.08 BMI/obesity T2D [88] 
36 rs16861329 ST6GAL1 intron 3 G A 1.09 T2D [65] 
37 rs6780569 UBE2E2 intergenic 3 G A 1.21 T2D [73] 
38 rs6815464 MAEA intron 4 C G 1.13 T2D [63] 
39 rs7656416 MAEA intron 4 C T 1.15 T2D [63,64] 
40 rs6813195 TMEM154 intergenic 4 C T 1.08 T2D [70] 
41 rs10010131 WFS1 intron 4 G A 1.14 T2D [4,89] 
42 rs4689388 WFS1 nearGene-5 4 T C 1.16 T2D [83] 
43 rs6446482 WFS1 intron 4 G C 1.11 T2D [25,89,90] 
44 rs1801214 WFS1 coding-missense 4 T C 1.13 T2D [25,89,90] 
45 rs459193 ANKRD55 intergenic 5 G A 1.08 T2D [62] 
46 rs702634 ARL15 intron 5 A G 1.06 T2D [70] 
47 rs4457053 ZBED3 intron of ZBED3-AS1 5 G A 1.08 T2D [25] 
48 rs1048886 C6orf57 coding-missense 6 G A 1.54 T2D [91] 
49 rs7754840 CDKAL1 intron 6 C G 1.17 T2D [25,27,59,60,66,73,92,93] 
50 rs7756992 CDKAL1 intron 6 G A 1.20 T2D [27] 
51 rs2206734 CDKAL1 intron 6 T C 1.20 T2D [25,27,59,60,66,73,92,93] 
52 rs4712523 CDKAL1 intron 6 G A 1.27 T2D [25,27,59,60,66,73,83,92,93] 
53 rs10946398 CDKAL1 intron 6 C A 1.12 T2D [25,27,59,60,66,73,92,93] 
54 rs7766070 CDKAL1 intron 6 A C 1.23 T2D [25,27,59,60,66,73,92,93] 
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Table 1. Cont. 
N T2D Risk SNP GENE/Nearest Gene Gene Location Chr RA OA OR TRAIT Refs. 
55 
rs2244020 
(rs9266650) 
HLA-B intergenic 6 G A 1.09 T2D [94] 
56 rs1535500 KCNK16 coding-missense 6 T G 1.08 T2D [63] 
57 rs3130501 POU5F1-TCF19 nearGene-5 6 G A 1.07 T2D [70] 
58 rs9505118 SSR1-RREB1 intron 6 A G 1.06 T2D [70] 
59 rs9470794 ZFAND3 intron 6 C T 1.12 T2D [63] 
60 rs17168486 DGKB intergenic 7 T C 1.15 T2D [62] 
61 rs2191349 DGKB/TMEM195 intergenic 7 T G 1.06 Fasting glucose, Homa B/T2D [81] 
62 rs6467136 GCC1-PAX4 intergenic 7 G A 1.11 T2D [63] 
63 rs4607517 GCK intergenic 7 A G 1.07 Fasting glucose/T2D/HOMA B [81] 
64 rs864745 JAZF1 intron 7 T C 1.10 T2D [4,80] 
65 rs849134 JAZF1 intron 7 A G 1.13 T2D [25,80] 
66 rs12113122 JAZF1 intron 7 G C 1.55 T2D [85] 
67 rs972283 KLF14 intergenic 7 G A 1.07 Reduced insulin sensitivity T2D [25] 
68 rs516946 ANK1 intron 8 C T 1.09 T2D [62] 
69 rs515071 ANK1 intron 8 G A 1.18 T2D Reduced beta-cell function [62,64] 
70 rs13266634 SLC30A8 coding-missense 8 C T 1.19 T2D [58] 
71 rs11558471 SLC30A8 UTR-3 8 A G 1.15 Fasting glucose, HOMA B T2D [25,58,59,81,87,92,93] 
72 rs3802177 SLC30A8 UTR-3 8 G A 1.26 T2D [25,58,59,81,87,92,93] 
73 rs896854 TP53INP1 intron 8 T C 1.06 T2D [25] 
74 rs10965250 CDKN2A/2B intergenic 9 G A 1.20 T2D [25,27,59,60,66,73,92,93] 
75 rs2383208 CDKN2A/2B intergenic 9 A G 1.19 T2D [25,27,59,60,66,73,92,93] 
76 rs7018475 CDKN2A/2B intergenic 9 G T 1.35 T2D [25,27,59,60,66,73,92,93] 
77 rs564398 CDKN2A/2B intergenic 9 T C 1.12 T2D [25,27,59,60,66,73,92,93] 
78 rs10757282 CDKN2A/2B intergenic 9 C T 1.14 T2D [25,27,59,60,66,73,92,93] 
79 rs10811661 CDKN2B intergenic 9 T C 1.20 T2D [25,59,60,66,68,80,87,92] 
80 rs7034200 GLIS3 intron 9 A C 1.03 Fasting glucose/T2D/HOMA B [81] 
81 rs7041847 GLIS3 intron 9 A G 1.10 T2D [63,66] 
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82 rs10814916 GLIS3 intron 9 C A 1.11 T2D [63,66,81] 
83 rs17584499 PTPRD intron 9 T C 1.57 T2D [95] 
84 rs2796441 TLE1 intergenic 9 G A 1.07 T2D [62] 
85 rs13292136 TLE4 (CHCHD9) intergenic 9 C T 1.11 T2D [25] 
86 rs553668 ADRA2A UTR-3 10 A G 1.42 T2D [96] 
87 rs10885122 ADRA2A intergenic 10 G T 1.04 Fasting glucose/HOMA B/T2D [81] 
88 rs12779790 CDC123, CAMK1D intergenic 10 G A 1.11 T2D [4,80] 
89 rs11257655 CDC123/CAMK1D intergenic 10 C T 1.15 T2D [66,69,80] 
90 rs10906115 CDC123/CAMK1D intergenic 10 A G 1.13 T2D [66,69,80] 
91 rs10886471 GRK5 intron 10 C T 1.12 T2D [66] 
92 rs5015480 HHEX intergenic 10 C T 1.13 T2D [25,58,59,92,93] 
93 rs1111875 HHEX/IDE intergenic 10 C T 1.13 T2D [59] 
94 rs7903146 TCF7L2 intronic/promoter 10 T C 1.35 T2D, fasting glucose,.2 h glucose [51] 
95 rs4506565 TCF7L2 intron 10 T A 1.34 Fasting glucose, HOMA B T2D 
[25,27,51, 
58–61,80,87,92,93,97–99] 
96 rs7901695 TCF7L2 intron 10 C T 1.37 T2D 
[25,27,51, 
58–61,80,87,92,93,97-99] 
97 rs1802295 VPS26A UTR-3 10 A G 1.08 T2D [65] 
98 rs12571751 ZMIZ1 intron 10 A G 1.08 T2D [62] 
99 rs11603334 ARAP1 UTR-5 11 G A 1.13 T2D fasting proinsulin levels/fasting glucose/ [100] 
100 rs1552224 CENTD2 intergenic 11 A C 1.14 T2D [25] 
101 rs11605924 CRY2 intron 11 A C 1.04 Fasting glucose/HOMA B/T2D [81] 
102 rs174550 FADS1 intron 11 T C 1.04 Fasting glucose/T2D/HOMA B [81] 
103 rs2334499 HCCA2 intergenic 11 T C 1.35 T2D [101] 
104 rs3842770 INS-IGF2 intron 11 A G 1.18 T2D - African American [94] 
105 rs5219 KCNJ11 coding-missense 11 T C 1.14 T2D [54,59,60,87,99] 
106 rs5215 KCNJ11 coding-missense 11 C T 1.14 T2D [54,59,60,87,99] 
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107 rs2237895 KCNQ1 intron 11 C T 1.45 T2D [71] 
108 rs231362 KCNQ1 intron 11 G A 1.08 T2D [25] 
109 rs163184 KCNQ1 intron 11 G T 1.22 T2D [62,71] 
110 rs2237892 KCNQ1 intron 11 C T 1.25 Reduced beta-cell function T2D [25,71,72,92,95] 
111 rs10501320 MADD intron 11 G C 1.01 T2D fasting proinsulin levels/fasting glucose [100] 
112 rs10830963 MTNR1B intron 11 G C 1.09 T2D [102] 
113 rs1387153 MTNR1B intergenic 11 T C 1.09 Reduced beta-cell function T2D [25,95,102] 
114 rs7138803 BCDIN3D/FAIM2 intergenic 12 A G 1.11 BMI/obesity T2D [88,103] 
115 rs11063069 CCND2 intergenic 12 G A 1.12 T2D [62] 
116 rs1153188 DCD intergenic 12 A T 1.08 T2D [80] 
117 rs1531343 HMGA2 intron of pseudogene 12 C G 1.10 T2D [25] 
118 rs9668162 HMGA2 intron 12 G C 1.26 T2D [85] 
119 rs7305618 HNF1A intergenic 12 C T 1.14 T2D [25,68] 
120 rs35767 IGF1 nearGene-5 12 G A 1.04 Fasting insulin/T2D/HOMA IR [81] 
121 rs10842994 KLHDC5 intergenic 12 C T 1.10 T2D [62] 
122 rs4275659 MPHOSPH9 intron 12 C T 1.06 T2D [70] 
123 rs7957197 OASL/TCF1/HNF1A intron of OASL 12 T A 1.07 T2D [25] 
124 rs7961581 TSPAN8, LGR5 intergenic 12 C T 1.09 T2D [4,80] 
125 rs9552911 SGCG intron 13 G A 1.63 T2D [104] 
126 rs1359790 SPRY2 intergenic 13 G A 1.15 T2D [69] 
127 rs2028299 AP3S2 UTR-3 15 C A 1.10 T2D [65] 
128 rs7172432 C2CD4A/B intergenic 15 A G 1.14 Reduced beta-cell function, T2D [73] 
129 rs7178572 HMG20A intergenic 15 A G 1.09 lean T2D [65,93] 
130 rs7177055 HMG20A intergenic 15 A G 1.08 T2D [62] 
131 rs8042680 PRC1 intron 15 A C 1.07 T2D [25] 
132 rs7403531 RASGRP1 intron 15 T C 1.10 T2D [66] 
133 rs4502156 VPS13C/C2CD4A/B intergenic 15 T C 1.07 fasting proinsulin levels T2D [100] 
134 rs11634397 ZFAND6 intergenic 15 G A 1.06 T2D [25] 
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135 rs7202877 BCAR1 intergenic 16 T G 1.12 T2D [62] 
136 rs8050136 FTO intron 16 A C 1.17 Increased BMI, reduced insulin sensitivity, T2D [25,60,61,80,87,93,99,105] 
137 rs9939609 FTO intron 16 A T 1.25 T2D (obese) [25,60,61,80,87,93,99,105] 
138 rs11642841 FTO intron 16 A C 1.13 T2D [25,60,61,80,87,93,99,105] 
139 rs4430796 HNF1B intron 17 G A 1.19 Reduced beta-cell function T2D [66,106-108] 
140 rs7501939 HNF1B intron 17 T C 1.09 T2D [106] 
141 rs391300 SRR intron 17 G A 1.28 T2D [95] 
142 rs4523957 SRR nearGene-5 17 T  1.27 T2D [95] 
143 rs8090011 LAMA1 intron 18 G C 1.13 lean T2D [93] 
144 rs17782313 MC4R intergenic 18 C T 1.06 BMI/T2D [88,103] 
145 rs12970134 MC4R intergenic 18 A G 1.08 T2D/BMI/waist circumference/insulin resistance [62,109] 
146 rs3794991 GATAD2A/CILP2 intron, intergenic 19 T C 1.12 T2D [62,85] 
147 rs8108269 GIPR intergenic 19 G T 1.05 T2D [62] 
148 rs3786897 PEPD intron 19 A G 1.10 T2D [63] 
149 rs10401969 SUGP1/CILP2 intron 19 C T 1.13 T2D [62,85] 
150 rs6017317 FITM2-R3HDML-HNF4A intergenic 20 G T 1.09 T2D [63] 
151 rs4812829 HNF4A intron 20 A G 1.09 T2D [65] 
152 rs5945326 DUSP9 intergenic X A G 1.27 T2D [25] 
153 rs12010175 FAM58A intron X G A 1.21 T2D [66] 
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Table 2. Genetic loci associated with glycemic traits. 
N SNPs Gene/Nearest Gene Gene Location Chr 
Effect
Allele 
Other 
Allele 
Effect TRAIT Refs. 
1 rs9727115 SNX7 intron 1 G A 0.0133 fasting proinsulin levels adjusted for fasting glucose [100] 
2 rs2785980 LYPLAL1 intergenic 1 T C 0.017 fasting insulin [110] 
3 rs4675095 IRS1 intron 2 A T 0.006/002 fasting glucose/HOMA-IR [81] 
4 rs2943634 IRS1 intergenic 2 C A 0.025 fasting insulin, CAD [110] 
5 rs1371614 DPYSL5 intron 2 T C 0.022 Fasting glucose  [110] 
6 rs11920090 SLC2A2 intron 3 T A 0.02 Fasting glucose/HOMA B/HBA1C [81] 
7 rs17046216 MSMO1 intron 4 A T 0.18; 0.19 Fasting Insulin; insulin resistance [111] 
8 rs4691380 PDGFC intron 4 C T 0.021 fasting insulin [110] 
9 rs6235 PCSK1 coding-missense 5 G C 0.0394/0.014 fasting proinsulin levels/Fasting glucose [100] 
10 rs13179048 PCSK1 intergenic 5 C A 0.018 Fasting glucose [110] 
11 rs4646949 TAF11 nearGene-3 6 T G 0.020 fasting insulin [110] 
12 rs6943153 GRB10 intron 7 C T 0.0154 FG, FI [26] 
13 rs4841132 PPP1R3B intergenic 8 A G 0.030 Fasting glucose [110] 
14 rs7077836 TCERG1L intergenic 10 T C 0.28; 0.34 Fasting Insulin ; insulin resistance [111] 
15 rs7944584 MADD intron 11 A T 0.021 Fasting proinsulin/Fasting glucose/Homa B [81] 
16 rs10838687 MADD intron 11 T G 0.0253 fasting proinsulin levels [100] 
17 rs1483121 OR4S1 intergenic 11 G A 0.015 Fasting glucose [110] 
18 rs2074356 HECTD4/C12orf51 intron 12    1-h plasma glucose [112] 
19 rs2293941 PDX1 - AS1 intron 13 A G 0.016 Fasting glucose [110] 
20 rs17271305 VPS13C intron 15 G A 0.07 2hr glucose/2-h insulin, adjusted for 2-h glucose [86] 
21 rs1549318 LARP6 intergenic 15 T C 0.0192 fasting proinsulin levels [100] 
22 rs4790333 SGSM2 intron 17 T C 0.0154 fasting proinsulin levels [100] 
23 rs10423928 GIPR intron 19 A T  
2 h glucose/Insulinogenic index/AUCins/gluc/2-h insulin, adjusted 
for 2 h glucose/T2D 
[86] 
24 rs6048205 FOXA2/LINC00261 intergenic/nearGene-5 20 A G 0.029 Fasting glucose [110] 
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Figure 2. T2D risk variants. X axis shows the chromosomal location, Y shows the effect 
sizes and Z axis shows the year of discovery. Only 1 risk variant was reported in 1998; there 
were 2 in 2002, and today, we have a total of ~153 T2D variants. 
 
Figure 3. T2D and glycemic trait associated variants. The variants are represented by gene 
names here, which could indicate that the location is present either in the gene, or in the 
vicinity of the gene. The black circle represents T2D, and the gene names in black in this 
represent variants only associated with T2D. The overlapping circles indicate additional 
reporting associations for that variant for instance, TCF7L2, KCNQ1, MTNR1B etc., are 
associated with T2D and also with beta-cell dysfunction. An ADCY5 variant is associated 
with 2 h insulin adjusted for 2 h glucose; 2 h glucose/T2D (in brown) *** variants in 
TMEM163 are also associated with fasting insulin, TCF7L2—associated with fasting and  
2 h glucose and MADD variants associated with fasting proinsulin, fasting glucose  
and HOMA-B.
Genes 2015, 6 102
 
 
4.1.4. Rare Variants 
Rare variants are more recent and therefore more likely to be those that arose lately in an extended 
pedigree. Of course, natural selection removes the more deleterious variants before they reach a high 
frequency; risk alleles for diseases should thus be enriched at lower frequencies. The idea that there are 
unique rare variant combinations in families and their role in disease etiology is referred to as “clan 
genomics” [113]. Current data suggests that the combined effects of rare and common variants contribute 
in varying degrees to disease causation, even linkage; in fact, rare alleles may explain the majority of 
heritability [114]. Next-generation sequencing provides even denser coverage of genetic variation 
rendering detection of causal rare variants more feasible. Whole genome sequencing (WGS) of 2,630 
Icelanders and imputation into 11,114 Icelandic cases and 267,140 controls followed by testing in Danish 
and Iranian samples revealed variants in PAM and PDX1 as risk of T2D [115] (Table 3). Array-based 
genotyping and exome sequencing on a small founder population from Greenland revealed a nonsense 
p.Arg684Ter variant (allele frequency of 17%) in TBC1D4 associated with higher concentrations of 2 h 
glucose and serum insulin [116]. Whole-exome sequencing in a Latino population revealed a rare missense 
variant in HNF1A (c.1522G > A [p.E508K]) was associated with type 2 diabetes prevalence [117]. 
Additionally, rare variants associated with glycemic traits were discovered through exome sequencing 
of 9,717 individuals from the METSIM study, Finland [118] (Table 3). 
Table 3. Rare risk and protective loci associated with T2D and glycemic traits. 
N SNPs GENE/Nearest Gene Gene Location Chr Refs. 
1 rs35658696 PAM coding-missense 5 [118] 
2 rs78408340 PAM coding-missense 5 [118] 
3 rs36046591 PPIP5K2 coding-missense 5 [118] 
4 p.Lys34Serfs*50 SLC30A8 coding-missense 8 [119] 
5 p.Arg138* SLC30A8 coding-missense 8 [119] 
6 rs3824420 KANK1 coding-missense 9 [118] 
7 rs505922 ABO Intronic 9 [118] 
8 rs60980157 GPSM1 coding-missense 9 [118] 
9 p.Leu5Val (20) ATG13 coding-missense 11 [118] 
10 p.Ile131Val (1) ATG13 coding-missense 11 [118] 
11 p.Gln249Pro (3) ATG13 coding-missense 11 [118] 
12 p.Arg392Trp (1) ATG13 coding-missense 11 [118] 
13 p.Leu427Gln (3) ATG13 coding-missense 11 [118] 
14 p.Gly434Arg (488) ATG13 coding-missense 11 [118] 
15 p.X406Gly (200) ATG13 coding-missense 11 [118] 
16 rs35233100 MADD coding-missense 11 [118] 
17 p.Arg279Cys (324) TBC1D30 coding-missense 12 [118] 
18 p.Pro746Leu (427) TBC1D30 coding-missense 12 [118] 
19 c.1522G > A [p.E508K] HNF1A coding-missense 12 [117] 
20 rs76895963 CCND2 intergenic 12 [115] 
21 rs75615236 CCND2 intergenic 12 [115] 
22 rs150781447 TBC1D30 coding-missense 12 [118] 
23 rs2650000 HNF1A Intergenic 12 [118] 
24 Chr. 13: g.27396636delT PDX1 coding-missense 13 [119] 
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25 p.Tyr416Cys (78) SGSM2 coding-missense 17 [118] 
26 p.Thr789Pro (3) SGSM2 coding-missense 17 [118] 
27 p.Val996Ile (236) SGSM2 coding-missense 17 [118] 
28 rs61741902 SGSM2 coding-missense 17 [118] 
4.1.5. Structural Variants 
Most studies to date have been limited to SNP leaving structural polymorphisms relatively unexplored. 
However, since common structural variants are likely to be tagged by surrounding SNPs, they are 
unlikely to explain a large proportion of missing heritability. A recent study identified a common copy 
number variation (CNV), CNVR5583.1 (TSPAN8), as associated with T2D [120]. This association could 
be convincingly replicated by previously typed SNPs that tag the CNV [80]. 
4.1.6. Protective Variants 
The average T2D risk variant frequency is 54% in the general population, which raises the question: 
Is T2D the default condition? If so, then does carrying protective variants makes a difference in the 
disease susceptibility? Studies have been performed to address this question but included controls that, 
despite a clustering of risk factors for T2D, have escaped the disease. A rare (0.66%) loss of function 
mutation (R138X) was detected in the SLC30A8 gene in the Botnia region from Finland and 
subsequently replicated in a massive effort applying the Exome chip to >150,000 individuals from other 
European countries. Also, the DeCode group had identified another LoF mutation, a frameshift mutation 
which also was enriched in the non-diabetic Icelandic population. The SLC30A8 gene encodes the islet 
zinc transporter 8 with a putative effect on insulin secretion. Notably, a common variant in the same 
gene increases susceptibility to T2D, whereas autoantibodies to T1D predispose to T1D. 
Collectively, carriers of these protein-truncating mutations have a 65% lower risk of T2D [119].  
Other studies based on Icelandic, Danish and Iranian populations identified a low frequency variant in 
CCND2 that reduced T2D risk by half [115]. Moreover, variants in TCF2 were found to be protective 
against T2D [106]. It is also likely that the more recent variants that are only a few generations old 
segregate in families and could be detected though sequencing in families. 
4.1.7. The Genetic Architecture of T2D 
Genetic architecture of a complex phenotype is defined by the number, frequencies and effect sizes 
of causal alleles. Many hypotheses have been proposed to define the genetic architecture of T2D:  
one hypothesis suggested that the unexplained heritability lies in a large number of common variants 
with low additive effects and that the disease represents the extremes of a normal distribution [121]. 
Another proposed that rare alleles might be responsible for effects observed with common variants 
(synthetic associations) and explain a majority of the heritability [113,122,123]. One argument against 
common and more so against rare variants is that they would have been removed from the population by 
natural selection [47]; however, this is not a valid argument for a disease like T2D whereby the 
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penetrance of the genetic effect depends strongly on interactions with the environment, especially since this 
environment has changed in recent years and the genetic risk variants could have been neutral or even 
beneficial before the introduction of the Westernized lifestyle. 
While extreme models are excluded by the present data based on epidemiological, linkage and 
GWAS, models wherein rare variants explain a little (<25%) or a lot (>80%) of heritability remain 
consistent [124]. Large next-generation sequencing studies in families will hopefully answer the questions 
about the role of rare variants in complex diseases. There is already substantial evidence for parent-of-origin 
effects on T2D risk, and studies are ongoing to explore this further. Structural polymorphisms and 
microRNAs add a further layer of complexity and have not yet been exhaustively studied. 
The genetic architecture could also be influenced by gene-gene interactions (epistasis) where rare, 
variants with high penetrance, could act jointly with common alleles to increase risk of disease.  
The extent of allelic heterogeneity seems to be less pronounced for the common form of T2D than for 
monogenic forms like MODY. Moreover, there could be differences in the genetic predisposition to T2D 
due to phenotypic heterogeneity within T2D cases. For instance, lean T2D cases are likely to carry a 
disproportionately high load of type 2 diabetes risk alleles [93]. 
4.2. Functions of Associated Genes 
Most identified diabetes loci have not been mechanistically tied to the disease. While loci are 
commonly referred to by the names of genes located close to them, only a few are close to strong 
biological candidates, e.g., the melatonin receptor (MTNR1B) and the insulin receptor substrate-1 (IRS1). 
For others, like TCF7L2 and GIPR, the evidence is quite strong that an intronic SNP is the causal SNP. 
Melatonin receptor 1B (MTNR1B) has been associated with both fasting glucose and T2D risk [102,125,126]. 
Melatonin works as a chronobiotic factor, adjusting the timing of the biological clock. Its receptors are 
present in the pancreas and melatonin is proposed to contribute to the nocturnal lowering of insulin in 
humans. The MTNR1B risk genotype is associated with impaired early insulin release to both oral and 
intravenous glucose and insulin secretion deteriorates over time in the risk allele carriers [125].  
The proposed mechanism by which MTNR1B polymorphism could predispose to T2D involves altered 
expression of MTNR1B in pancreatic -cells leading to decreased cAMP/cGMP concentrations via G 
proteins and, thereby, impaired insulin secretion. 
The insulin receptor substrate 1 (IRS1) gene encodes a protein that mediates insulin’s control of 
various cellular processes by transmitting signals from the insulin receptor to intracellular signaling 
pathways. The C allele of rs2943641 has been shown to be associated with insulin resistance and 
increased risk of diabetes. The genetic variant causes reduced basal levels of IRS1 protein and decreased 
insulin induction of IRS1-associated phosphatidylinositol-3-hydroxykinase activity in human skeletal 
muscle biopsies [83]. 
TCF7L2 is a transcription factor playing an important role in the Wnt signaling pathway. The risk 
allele is associated with decreased insulinogenic index and lower disposition index, suggesting a reduced 
capacity for insulin secretion in relation to insulin sensitivity. Since it was identified as a diabetes gene, 
it has been shown to be important for several vital functions in the pancreatic islet, including pancreas 
development, determination of beta-cell mass, maintenance of the secretory function of mature  
beta cells, and regulation of insulin production and processing [127,128]. 
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The incretin hormone GIP (glucose-dependent insulintropic polypeptide) promotes pancreatic -cell 
function by potentiating insulin secretion and -cell proliferation. The GIP receptor (GIPR) locus 
showed association to postprandial insulin levels in a meta-analysis performed by the MAGIC 
consortium but was surprisingly not associated with risk of diabetes in the DIAGRAM+ study [25,86]. 
The reason seems to be that the same variant results in decreased BMI, which neutralizes the effect of 
the SNP on risk of T2D. GIP influences expression of the inflammatory cytokine OPN in islets, which 
in turn has protective effects on -cell proliferation and potentially apoptosis [129]. 
Many of the other identified loci can be sub-grouped based on their association with other phenotypes 
with a key role in T2D etiology. Exploration of the effects of T2D-associated variants on glucose and 
insulin traits in non-diabetic populations has shown that most of the known loci act through an effect on 
insulin secretion rather than insulin resistance (Table 1) [25,130–132]. 
Fasting glucose-raising alleles of the MADD, GIPR, GCK, FADS, DGKB, PROX1, TCF7L2, 
SLC30A8 and C2CD4B loci have all been associated with either abnormal insulin processing or 
secretion, whereas GCKR and IGF1 are associated with OGTT-based disposition indices and -cell 
function [131]. The DIAGRAM+ consortium observed that three loci (TCF7L2, ARAP1 and CDKAL1) 
were associated with reduced fasting insulin also suggestive of -cell dysfunction, whereas the T2D risk 
alleles at PPARG, FTO, IRS1 and KLF14 were associated with higher fasting insulin, indicating a 
primary effect on insulin action [25]. 
Translational Studies 
The ADRA2A (adrenergic receptor alpha 2) locus was recently identified as a T2D risk locus after 
first having been positionally mapped in congenic GK rats where it was associated with impaired insulin 
granule docking and reduced -cell exocytosis [130]. Human carriers of the ADRA2A risk variant 
(rs553668) have reduced fasting insulin and decreased insulin secretion as a consequence of increased 
expression of the ADRA2A receptor in pancreatic islets. It is well known that epinephrine excess can 
suppress insulin secretion and cause diabetes. The 2AAR antagonist yohimbine enhances insulin release 
in vitro in islets from organ donors carrying the risk allele to levels similar to those in non-risk carriers. 
A randomized clinical study was performed blocking 2AAR pharmacologically to increase insulin 
secretion T2D patients with the rs553668 risk allele. Yohimbine administration enhanced 30 min insulin, 
corrected insulin response and disposition index in the risk group, making secretion similar to patients 
carrying the low-risk allele. Insulin secretion defect in patients carrying the ADRA2A risk genotype could 
be corrected by 2AAR antagonism [133]. This demonstrated the potential application of genetic risk 
variants to guide therapeutic interventions that target the underlying pathophysiology: one step closer to 
individualized medicine. 
5. Pitfalls 
5.1. Heritability Estimates 
Heritability parameters facilitate understanding the genetic architecture of complex traits such as 
T2D. However, the >80 loci identified explain less than 20% of the heritability of T2D. There are many 
possible explanations for the missing heritability, including assumptions made about the genetic 
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architecture of the disease and the definitions of heritability. The estimations of heritability explained 
assumes that only additive affects determine disease risk and that the risk follows the liability threshold 
model, i.e., that the genetic and environmental effects sum up to form a normal distribution of liability 
and that disease arises in individuals surpassing a certain threshold in the distribution [134]. If these 
assumptions are not true, the estimate of heritability explained will not be correct.  
Intrauterine effects can also affect heritability estimates because monozygotic twins are often 
monochorionic which results in growth retardation compared to dizygotic twins, and low birth weight is 
associated with increased risk of T2D later in life. Furthermore, there could be other explanations to the 
“missing heritability” problem. However, one should keep in mind that heritability can only be estimated 
from the most recent generations for which information on affection status is available, whereas most of 
the variants studied thus far are ancestral variants hundreds of generations old. We do not know whether 
these ancestral variants (that have modest effects and have escaped purifying selection) can really 
explain the diabetes epidemic we see in the most recent generations or whether this can be ascribed to 
rare variants with stronger effects. 
Moreover, heritability estimates are based on “top” SNPs from GWAS associations; novel methods 
have been proposed which take into account the (i) scale 0–1 scale as opposed to liability (2) ascertainment 
bias and (3) quality control of the GWAS SNPs. Estimating the proportion of variance explained by all 
SNPs in GWAS as opposed to only the most significantly associated SNPs could result in a more detailed 
estimate of heritability [135]. Applying an approach that considers all SNPs on the chip could in fact 
explain a much larger proportion of the “narrow-sense” heritability (>50%) supporting the existence of 
numerous yet unidentified loci with smaller effects [25,136,137]. 
5.2. Parent of Origin Effects 
The risk of T2D in offspring is greater if the mother has T2D compared to if the father is affected in 
contrast to T1D, where the risk of T1D in offspring is greater if the father is affected [138,139].  
Sex-specific parental effects have been reported for insulin response to the oral glucose load, with male 
offspring of diabetic mothers showing the lowest insulin values, as well as influencing HDL 
concentrations [138]. One potential explanation for this could be preferential parental specific 
transmissions of risk alleles to offspring, which is often associated with DNA methylation and 
imprinting. Epigenetic modifications have the potential to be stable and heritable across cell divisions 
and [140,141] manifest as parent-of-origin effects. A large-scale family-based study on the Icelandic 
population determined that variants in KCNQ1 and KLF14 show stronger effects on T2D when the  
risk allele is transmitted from the mother than from the father [101,142] and was replicated in later 
studies [143] including our own. 
The conflict hypothesis suggests that imprinting arose due to a genomic tug-of-war between mothers 
and fathers over the use of maternal resources in the fetus. The paternal imprinting maximizes the utilization 
of intrauterine resources to the offspring which would increase his evolutionary fitness whereas the 
maternal imprinting tries to minimize this in order to conserve it for her future offspring [144]. 
Conversely, the co-adaptation hypothesis suggests that imprinted genes coevolve to optimize parental 
care of offspring. While there is insufficient evidence to support either theory, the significant role of 
imprinting in defining paternal and maternal effects has nevertheless been consistently established [145]. 
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The intrauterine environment plays a significant role in determining fetal programming. It has been 
shown that poor nutrition can affect fetal growth, can produce permanent changes in glucose-insulin 
metabolism, and often results in low birth weight [146] This can induce permanent changes in 
metabolism and affect chronic disease susceptibility as proposed by the DoHAD hypothesis [147].  
If this intrauterine programming results in a reduced -cell mass, it could predispose to diabetes later in 
life when the insulin requirements increase as a consequence of obesity resulting in insulin resistance. 
KCNQ1 could represent an example of fetal programming wherein the maternally expressed gene was 
mono-allelically expressed in fetal tissues and bi-allelically expressed in adult tissues [148]. 
Dissection of genetic parent-of-origin effects requires genotype data from families and only 
heterozygous parents are informative yielding reduced power for relatively rare variants. However,  
long-range phasing and imputation methods allow for predicting genotypes with a great likelihood, thus 
making this a valuable method to find “surrogate” parents even if DNA exists from only a few family 
members. When the paternal and maternal allele have effects in opposite directions—as, for instance  
in a situation where the maternal allele could confer risk while the paternal allele could be  
protective—such an association would be almost impossible to detect in a traditional case-control 
GWAS. However, some novel POE detection methods allow detection of imprinting effects from 
differences in the phenotypic variance of heterozygotes in very large case-control studies [149].  
Parent-of-origin effects could explain a large portion of the missing heritability and must be taken into 
consideration in investigations of genetic T2D susceptibility. 
5.3. GeneGene and GeneEnvironment Interactions 
Genegene interactions, or epistasis, have been suggested as a possible explanation for difficulties in 
replicating genetic association in complex diseases [150]. The standard statistical methods used in 
association studies are usually limited to analysis of single marker effects and thereby do not account 
for interactions between markers. Previous attempts to study epistasis in complex diseases have focused 
on interactions between candidate regions [151,152]. However, the recent abundance of GWAS data has 
made a comprehensive search across the genome more feasible. Some studies have attempted to account 
for epistasis in GWAS using a two-step approach in which significant SNPs are tested against each other 
or against all other SNPs in the study with variable results [153,154]. The main problem when studying 
epistasis is power, since interaction between loci with modest effects is difficult to detect without 
extremely large sample sizes. However, some studies have pointed at novel tests to increase power [155]. 
Thorough studies in diabetes addressing epistasis using this approach are missing. Furthermore, a recent 
paper by Eric Lander and co-workers provided compelling evidence that genegene interaction can also 
contribute to missing heritability by causing “phantom heritability” that inflates the estimated narrow 
sense heritability of the trait [156]. 
Geneenvironment interactions are equally difficult to study but are likely to play an important role 
in T2D development. The epidemic of T2D only dates back 50 years, and it is quite obvious that during 
this period that only the environment, and not the genes, have changed. However, the genetic architecture 
determines our response to the environment. Genetic variants could affect specific metabolic processes 
to make an individual more susceptible to the harmful effects of a poor diet but also personality traits 
that make an individual more or less likely to over-consume and live a sedentary lifestyle. It will however 
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be a formidable task to identify the environmental triggers for most of the genetic variants increasing 
susceptibility to diabetes as this will require very large studies with precise information on diet, exercise, 
energy expenditure, etc. 
5.4. Epigenetics 
The environment can also influence the expression of the genome, and ultimately the phenotype, via 
the epigenome. Even though the DNA sequence is not changed, the phenotype is altered by epigenetic 
modifications of gene expression by mechanisms including methylation of DNA, posttranslational 
modification of histones, or activation of microRNAs. Changes to the phenotype can be at the level of 
the cell, tissue, or whole organism. 
It is tempting to speculate that environmental factors such as diet and exercise can change the level 
of DNA methylation and thereby cause changes in gene expression, but evidence that DNA methylation 
contributes to the increase in T2D is still lacking. Epigenetic mechanisms may however play a role in 
progression of the disease by inducing glucotoxicity in islets and predispose to diabetic complications [157]. 
Elevated glucose is a prerequisite to this condition and it is well established that cells can memorize 
changes in glucose concentrations. For example, two large studies, the UKPDS and DCCT studies, 
showed that an initial good metabolic control was associated with reduced frequency of diabetic 
complications decades later. The advanced “metabolic memory” hypothesis suggests that this is because 
glucose can induce histone modifications in endothelial cells that can be remembered long after [158]. 
5.5. Non-Coding RNAsmicroRNAs 
Non-coding RNAs have recently emerged as important regulators of gene expression and function. 
MicroRNAs (miRNAs) naturally regulate programs of gene expression. Altered miRNA function has 
been shown to contribute to human disease, and manipulation of specific miRNAs is now being explored 
as a novel therapeutic modalities [159]. The efficiency of miRNAs binding to target transcripts depends 
on both the sequence and the intra-molecular structure of the transcript. SNPs can contribute to 
alterations in the structure of regions flanking them, thereby influencing the accessibility for miRNA 
binding. Several studies have implicated miRNAs in diabetes and inflammation and common SNPs 
change the target sequence of miRNAs in several T2D susceptibility loci (http://miracle.igib.res.in/ 
dbSMR) [160,161]. Other forms of non-coding RNAs, such as piRNAs (PIWI-interacting RNAs), 
snoRNAs (small nucleolar RNAs), lincRNAs (long intergenic non-coding RNAs), and lncRNAs (long 
non-coding RNAs), might also contribute to the development of diabetes. For example, the CDKN2A/B 
region on chromosome 9 is associated with T2D, as well as cardiovascular disease and a number of other 
disorders. This region harbors an lncRNA, ANRIL (non-protein coding CDKN2B-AS1 CDKN2B 
antisense RNA 1), which can potentially modify and explain some of these associations [162]. 
5.6. The T1D-T2D Paradox 
T1D and T2D can be considered two extremes of the diabetes spectrum and share a few similarities 
in manifestation of underlying physiology including hyperglycemia, insulin deficiency and development 
of complications. However, the genetics of T1D and T2D vastly differ, with very few T2D susceptibility 
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loci showing an association with T1D. Notable exceptions include the PPARG Pro12Ala variant, 
MTNR1B, HNF1A, GLIS3, 6q22.32 and novel loci near the MHC, which harbor the HLA class II genes 
associated with about half the T1D risk [70,163–165]. Based on these studies, the mechanisms underlying 
T1D and T2D appear to be intrinsically distinct. The distribution of T2D risk SNPs should be more 
random in a T1D patient; however, this does not seem to be the case. The strongest T2DSNP in the 
TCF7L2 gene almost seems to protect from T1D. T1D risk variants for BCAR1, GLIS3 and  
RAD51L1 were protective for T2D whereas for those in C6orf173, COBL and C10orf59, the effects were  
coincident [62]. Also, it has been reported that APOC3 haplotypes increase risk of T1D; however, the same 
variants increase risk of T2D in lean carriers while having a protective effect in overweight carriers [166]. 
Common variants in SLC30A8 are associated with an increased risk of T2D, and rare variants with a 
protective effect [58,119]. Puzzlingly, SLC30A8 was also found to be a major autoantigen eliciting  
60%–80% autoantibodies in new-onset T1D patients [167]. 
Curiously, gene variants associated with T1D underwent recent positive selection and have been 
increasing in prevalence. There is more selection in alleles increasing, rather than decreasing, susceptibility 
to T1D. This is indicative of an evolutionary benefit, wherein these variants were possibly protective 
against viruses and bacterial infections. However, no such link has been reported for type 2 diabetes risk 
variants, as could be expected from the thrifty genotype hypothesis [168]. In terms of genetics, T2D 
seems to have more in common with that of cancer rather than T1D [169]. It has been suggested there 
may rather be a specific yinyang relationship between cancer and T2D, with too much cell proliferation 
resulting in cancer and insufficient proliferation of pancreatic islets resulting in T2D [169]. 
LADA (latent autoimmune diabetes in adults) is considered an intermediary form between T1D and 
T2D, also referred to as type 1.5 diabetes. There is much less information available as to the genetic 
basis of LADA compared to T1D and T2D. One way to understand this would be to assess to what extent 
LADA shares genetic similarities with T1D and T2D. The HLA locus, conferring 50% of the genetic 
susceptibility of T1D also shows similar associations with LADA, with a few differences. The T1D 
variant PTPN22 shows a weak association with LADA. Data on the INS class I variable number tandem 
repeats (VNTRs) has been inconclusive and associations have been reported with both T1D and T2D 
wherein the short tandem repeat is associated with T1D and the long with T2D. While previously several 
T1D-associated variants could be tested for association with LADA, it was not until the discovery of the 
common variant in the TCF7L2 gene being strongly associated with T2D that the genetic contribution 
of T2D to LADA could really be tested. This variant is clearly associated with LADA and T2D but not 
with T1D. This indicates that LADA is indeed a genetic admixture of T1D and T2D. 
There are more lessons to be learned from differences between T1D and T2D rather than similarities. 
Elucidating the genetic heterogeneity of the spectrum of diabetes disorders will help us in understanding 
the mechanisms underlying the phenotypic heterogeneity of diabetes and would be a step towards 
individualized therapy. 
5.7. Systems Biology 
A restricted focus on the genome through GWAS provides limited insights into the molecular 
mechanisms driving disease and is akin to a snapshot of the genetics of the disease. To obtain an 
understanding of disease pathogenesis, it is important to analyze the GWAS data in the context of 
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complementary follow-up analyses including DNA methylation and histone modifications, expression 
profiling under conditions relevant for the disease, related protein analysis, and analysis of  
genotypephenotype associations. Global transcriptome profiling in relevant tissues such as pancreas 
has facilitated identification and cataloging of a wide array of transcription-based events in the 
pathogenesis of T2D [170]. For example, by combining GWAS information with metabolomics, it has 
been possible to identify strong associations between SNPs and metabolic reactions that otherwise would 
have been missed [171]. Network or pathway-based approaches, including enrichment in pre-defined 
pathways by, for example, KEGG [172] (http://www.genome.jp) and Gene Ontology (GO) 
(http://www.geneontology.org), have also been used to identify disease genes for various diseases. Thus, 
an integrative approach of several data types is likely to discover disease genes that would not be 
identified by the use of classical GWAS approaches. This was also illustrated in a recent study of human 
islets identifying novel candidate genes for T2D based upon expression differences and co-expression 
with known T2D genes as well as proteinprotein interaction analyses [173,174]. Integration of GWAS 
data with such data could therefore facilitate a systems-based understanding of the pathogenic mechanisms. 
6. Conclusions 
The technical revolution in the field of genetics has allowed identification of numerous genetic 
variants that associate with T2D. The genetic landscape of T2D susceptibility is as yet incomplete, thus 
far only explaining a small proportion of the total heritability of diabetes. Many possibilities to dissect 
the architecture of T2D etiology have emerged in the form of large-scale genetic studies, meta-analyses 
and sequencing in families. It has already greatly contributed to our understanding of disease mechanisms 
by identifying pathways that could not be linked to diabetes by existing hypothetical models, even 
though many genetic findings are very recent and have yet to make their contribution to our knowledge 
about diabetes pathogenesis. However, one must bear in mind that diabetes is probably a much more 
diverse disease than the current subdivision into T1D and T2D implies and more precise subdivision 
into subgroups may both facilitate the investigation of T2D genetics and pave the way for more 
individualized treatment. A holistic systems biology approach will also be required to obtain a complete 
picture of how genetic variation leads to diabetes. The rapid technology development during the past 
years holds promises that this will be possible in a not-too-distant future. 
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